News for LGND Stock

Ligand Announces 2025 Investor Day in New York City Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 Ligand Reports First Quarter 2025 Financial Results Ligand to Participate in May Investor Conferences Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics Ligand to Participate in March Investor Conferences Ligand Reports Fourth Quarter and Full Year 2024 Financial Results Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance Ligand to Present at Stifel 2024 Healthcare Conference Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 Ligand to Acquire APEIRON Biologics AG for $100 Million Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults Ligand to Participate in Upcoming Investor Conferences Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million Ligand To Report Third Quarter 2023 Financial Results On November 8 Ligand Acquires Assets of Novan, Inc. for $12.2 Million Ligand Appoints Martine Zimmermann to its Board of Directors Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials Ligand To Report Second Quarter 2023 Financial Results On August 8 Ligand Offers $15 Million to Acquire Assets of Novan, Inc. Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) OmniAb Reports First Quarter 2023 Financial Results and Business Highlights Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Ligand Reports Fourth Quarter and Full Year 2022 Financial Results Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial Ligand to Report Fourth Quarter Financial Results on February 22 Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum Ligand Provides Highlights from its Investor and Analyst Day Event Ligand Pharmaceuticals Names Director Todd C. Davis as CEO Ligand to Hold Investor and Analyst Day on December 13 Ligand Reports Third Quarter 2022 Financial Results Ligand Announces Completion of OmniAb Spin-Off Ligand Distribution of OmniAb Complete and Business Combination Closed Ligand to Report Third Quarter Financial Results on November 7 Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma OmniAb Business Combination Approved by APAC Shareholders Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Ligand to Report Second Quarter Financial Results on August 8 Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors Ligand Reports First Quarter 2022 Financial Results Ligand to Report First Quarter Financial Results on May 4 Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Ligand Reports Fourth Quarter and Full Year 2021 Financial Results Ligand to Report Fourth Quarter Financial Results on February 17 Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy Ligand and GSK Expand Global Collaboration and License Agreement Ligand Reports Third Quarter 2021 Financial Results Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company Ligand to Report Third Quarter Financial Results on November 9, 2021 Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™ Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy Ligand Reports Second Quarter 2021 Financial Results Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes Ligand to Report Second Quarter Financial Results on July 29, 2021 Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors Ligand Reports First Quarter 2021 Financial Results Ligand to Report First Quarter Financial Results on May 3, 2021 Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis Ligand’s Fourth Quarter Financial Results to be Reported February 3rd Ligand Receives Milestone Payment from Merck Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients Ligand Reports Third Quarter 2020 Financial Results Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment Ligand Provides Highlights from Today’s Investor Day Event Ligand’s Third Quarter Financial Results to be Reported October 30th Ligand to Divest Vernalis Research Operations Ligand to Host Virtual Investor Day on October 20th Ligand Completes Acquisition of Pfenex Inc. Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.